SpaceX Is Nearing Its IPO Price. Time to Buy?

Space Exploration Technologies (SpaceX) shares nearly returned to IPO pricing, falling to just below $138 versus an IPO price of ~$135, about a month post-launch. Despite noted long-term upside (Starlink scale and potential space data centers), the article flags steep valuation risk: trailing P/S is ~96, with bullish revenue-growth assumptions implying a ~46x forward P/S (or ~25x one-year sales multiple if price stays flat). It concludes SpaceX is likely priced for years of growth and recommends investors avoid until valuation compresses.

Analysis

The market is pricing this like a near-monopoly with very long-dated optionality, so the real risk is not a slow fundamental bleed but a valuation air pocket if growth normalizes even modestly. At these multiples, a 5-10% miss on forward sales or any sign that monetization is constrained by launch cadence, churn, or capital intensity can trigger 20-30 turns of multiple compression. Near term, price action will be driven more by float/flow and any post-IPO supply than by operating news.

The bigger second-order effect is on adjacent public comparables: if investors decide they do not need to pay a 90x-sales premium for space exposure, capital should rotate toward cheaper listed proxies with real cash generation, while unprofitable space names become harder to fund. That argues for relative-value weakness in high-beta satellite/launch names and relative support for defense primes or established connectivity assets that offer similar thematic exposure without the duration risk. This is also a warning shot for Musk-adjacent optionality trades; the market may start discounting "story" more selectively.

Contrarianly, the bearish case may be overstating multiple risk and understating scarcity value: launch dominance plus government-backed demand can sustain a premium if revenue growth remains self-funding. What would falsify the bear case is a clean quarterly print with unchanged forward growth and improving margin economics; what would reverse it is any secondary, guidance reset, or evidence that the growth curve is flattening faster than expected. If there is no near-term catalyst, this can stay expensive longer than valuation models imply, but the asymmetry worsens sharply on any disappointment.

Key Decisions for Investors

• No direct SPCX position until borrow/liquidity and lockup dynamics are clearer; if it rallies post-IPO, consider a 2-3 month put spread rather than a naked short to express downside from a single disappointment.
• Relative-value: long MU on any market pullback as a cheaper growth alternative to speculative premium names; use SPCX weakness as a timing signal for rotation into lower-multiple semis.
• If you want thematic space exposure, prefer long LMT/NOC over unprofitable space-beta names; this is a lower-volatility way to own government/space spending over 6-18 months.
• Short a basket of high-beta space challengers (e.g., RKLB/ASTS if borrow is available) against a long defense/telecom basket; thesis breaks if SPCX prints sustained >100% revenue growth with no margin deterioration.
• Set an alert for the first post-IPO quarterly update: if guidance or gross margin disappoints, expect the first meaningful de-rating; if it beats cleanly, the short case is deferred, not invalidated.